Results reported
As filed · Outcome of Board Meeting
EarningsMajormateriality 75 out of 100
What happened
FactA DhanukaGroup Company.
Why it matters
CapitSignal interpretationReported results are the point at which prior management commitments become checkable against audited or reviewed numbers.
What management said before
Prior statements by this company that CapitSignal has recorded changing.
Capex
DelayedEarlierFY26
We'll probably have the exact number, say, after a few months' time.
NowFY27
as our cefiderocol project will get started, say, in the next year, then we will take validation batches and hopefully, after two years, we would be able to -- once we are able to register the product from our side, we would be able to supply some percentage from our side.
Change
FactTimeline delay
Implication
CapitSignal interpretationThe earlier statement indicated that the exact capex number would be available in a few months, while the current statement suggests that the project will start next year and take two years for validation before supply can begin.
Watch next
Fact- Margin trend against the prior period
- Cash from operations against reported profit
- Whether prior guidance is reaffirmed
- Hopefully, within this quarter, we should announce one. (management committed by Q4 FY26)
- The first sales actually would be to Orchid itself internally. (management committed by Q1 FY27)
Evidence
- Orchid Pharma Limited has submitted to the Exchange, the financial results for the period ended Jun 30, 2026.(opens the original filing in a new tab)
- Earlier statement · FY26
- Latest statement · FY27
- Earlier statement · FY27
How CapitSignal classified this
- Reasoning:
- RESULTS base 68; +2 corroborating keywords; +5 quantified amount; matched on subject
- Matched on:
- the filing's own subject line
- Confidence in the event type:
- 90%